Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 0.69 |
| ▸ | HTR2C | P28335 | 3/20 | 0.69 |
| ▸ | GAA | P10253 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12077352 | 0.96 | ALDH1A1 (0.93) | ALDH1A1MEN1KMT2AKDM4EHTR2A | |
| SCHEMBL2505847 | 0.91 | ALDH1A1 (0.83) | ALDH1A1MEN1KMT2AKDM4EHTR2A | |
| SCHEMBL12418056 | 0.90 | ALDH1A1 (0.82) | ALDH1A1MEN1KMT2AKDM4EHTR2A | |
| SCHEMBL28770811 | 0.84 | ALDH1A1 (0.72) | ALDH1A1MEN1KMT2AKDM4EHTR2A | |
| SCHEMBL9303072 | 0.84 | ALDH1A1 (0.73) | ALDH1A1MEN1KMT2AKDM4EHTR2A | |
| SCHEMBL4742374 | 0.83 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2AKDM4EHTR2A | |
| SCHEMBL3485687 | 0.83 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2AKDM4EHTR2A | |
| SCHEMBL19563418 | 0.83 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2AKDM4EHTR2A | |
| SCHEMBL16059927 | 0.83 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2AKDM4EHTR2A | |
| SCHEMBL8349997 | 0.81 | ALDH1A1 (0.69) | ALDH1A1MEN1KMT2AKDM4EHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040132809-A1 | Cell adhesion inhibitors | BIOGEN, INC. | 2004-07-08 | — | — | US | claimed |
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-8106045-B2 | 2-morpholino-4-pyrimidone compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-31 | — | — | US | disclosed |
| US-8106045-B2 | 2-morpholino-4-pyrimidone compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-31 | — | — | US | disclosed |
| WO-2009082346-A1 | NEW ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS AND USES IN TREATMENTS OF OBESITY AND DIABETES MELLITUS - 087 | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| US-20090124618-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MITSUBISHI PHARMA CORPORATION (JP) | 2009-05-14 | — | — | US | disclosed |
| US-20090124618-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MITSUBISHI PHARMA CORPORATION (JP) | 2009-05-14 | — | — | US | disclosed |
| CN-101146770-A | 2-phenyl indoles as prostaglandin D2 receptor antagonists | AVENTIS PHARMA INC (US) | 2008-03-19 | — | — | CN | disclosed |
| WO-2006028290-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MITSUBISHI PHARMA CORPORATION (JP) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132809-A1 | Cell adhesion inhibitors | VCAM1, ICAM1, EPCAM | ALDH1A1 631/4885MEN1 3126/4885KMT2A 2350/4885 |
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | ALDH1A1 592/4885MEN1 4160/4885KMT2A 3000/4885 |
| US-20090124618-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MAPT, PSEN1, PSEN2 | ALDH1A1 3276/4885MEN1 1278/4885KMT2A 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.